Navigation Links
Scleroderma Cure Still In Oscillation

According to a recent study, an old drug promises to slow down the progress of the dreadful autoimmune disease scleroderma or systemic sclerosis//.

About 3,00,000 Americans were found to be affected by the fatal disease Scleroderma, which destroys our system by hardening and thickening the skin and in many times it completely damages the lungs and other related organs. Nearly 80% of affected people have lung damaged more often it includes women only.

When comparing the benefits with after effects of a usual drug named cyclophosphamide, or Cytoxan, used to treat cancer and some autoimmune disorders, only minimum benefits were evidenced.

The study authors reported that 158 scleroderma patients from the country’s hospital were assigned at random into 2 groups, which includes experimental group (taking Cytoxan pills) and control group (taking only dummy pills) 1 per day for a period of 1 year. Throughout the year they were monitered, and the results show only a little improvement in using Cytoxan group of drugs although there seems a statistically significant difference – said Dr. Philip J. Clements, a rheumatologist at the University of California, Los Angeles, who was a co-author of the study.

One among the adverse effects of using Cytoxan group of drugs was low white blood cell count, says author.

Dr. Clements reported in an interview that beyond many studies Cytoxan with little side effects for scleroderma patients only proves in part to benefit scleroderma patients with lung damage.

Since having adverse effects in the long-term use of the drug, researchers urged to carry out a follow up of this study in a fast rate.


'"/>




Page: 1

Related medicine news :

1. Cancer Drug to Treat Scleroderma Lung Disease
2. Link between C-section Delivery and Stillbirth
3. Estimates For Number Of HIV/AIDS Deaths In India Still Not Available
4. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
5. Past President Narayanans Condition Still Critical
6. LASIK Treatments Still To Reach Common Man
7. Hurricane Hangover: Katrina Still Haunts
8. Tuberculosis Is Still A Major Health Threat In Africa
9. Despite More Studies Researchers Are Still Confound With ADHD
10. Children Are Exercising Much Harder, But Are Still Obese
11. Study Shows That More Than 3 Million Stillbirths Occur Worldwide Every Year
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 2016 , ... 1105 Media’s Live From program has been ... competition. Live From won in the Use of Social Media category. The Folio: ... undertaken by the media industry’s most innovative marketing professionals. , Conceived ...
(Date:12/7/2016)... ... 2016 , ... Gensuite is honored to be selected as ... Product Launch category. Gensuite’s entry on their EZ Scan feature detailed the tool’s ... Training Group is a professional event and training provider based in the United ...
(Date:12/7/2016)... ... ... Road To Restoration”: an informative and enlightening book for those who believe that ... “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, seventy-one-year-old ... you could reach out for, and grab, on the old carousels. If you ...
(Date:12/7/2016)... ... ... Rides a Train” allows readers to tag along on a special shopping trip for ... creation of published author, Janet Morrison, who has been writing mostly poetry, essays, professional ... series is her first attempt at writing for children. Janet, Fred, and two cats ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg ... the International Probiotic Association’s Washington DC workshop on November 2nd. The conference was ... dialog regarding probiotic dietary supplement regulations. , Dr. Leyer spoke about two ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses from ... than one-third (38%) of patients with non-small cell lung cancer ... factor receptor (EGFR) genetic mutation status. The findings of the ... LBA ID #6067 #P3.02b ) at the 2016 World ... . The survey results revealed an overall ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
Breaking Medicine Technology: